Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

To join this study, you would need to be an adult, aged 18 or over. You must have a confirmed diagnosis of certain blood cancers like Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia, or a specific type of Myelodysplastic Syndrome, and your cancer must have either come back or not responded to standard treatments. You also need to be generally well enough to take part, meaning you can do most of your normal daily activities without too much difficulty, and your body organs like your liver and kidneys are working properly.

There are also some reasons why you might not be able to join. For example, if you've recently had chemotherapy, other anti-cancer treatments, or major surgery, there would be a waiting period before you could start. You also can't be taking certain medications that might interfere with how the study drug works, including some strong medications that affect your liver or cholesterol-lowering drugs (statins) which would need to be stopped before starting the study. The study also cannot include people with uncontrolled illnesses or certain heart conditions.

The details of what specific assessments or visits are involved are not fully outlined in this summary. However, typically in studies like this, you would likely have regular appointments at the clinic for check-ups. These visits might include blood tests to see how the drug is affecting your body and the cancer, physical examinations, and scans. You would be given the study medication, CCS1477, and possibly other approved medications depending on the study group you are in. The total duration of your participation would be explained by the study team, and there would usually be a follow-up period after you stop taking the study medication to monitor your health. All aspects of your care and the reasons for your visits will be explained in detail by the study team.